London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
You will only have one login account. Registering with multiple accounts is not allowed. Any user found to have more than one account on this site will have all, and any future accounts suspended permanently.
Your email and password must only be used by you. If a post is made under your account, it will be considered that it was posted by yourself.
Your account nickname must not be the same, or contain, listed company names or board members' names.
While debating and discussion is fine, we will not tolerate; rudeness, swearing, insulting posts, personal attacks, or posts which are invasive of another's privacy.
You will not;
discuss illegal or criminal activities.
post any confidential or price sensitive information or that is not public knowledge.
post misleading or false statements regarding the share price and performance. Such posts are deemed as market abuse, and may be reported to the appropriate authorities.
post any private communication, or part thereof, from any other person, including from a member of the board of directors of a listed company. Such posts cannot be verified as true and could be deemed to be misleading.
post any personal details (e.g. email address or phone number).
post live price or level 2 updates.
publish content that is not your original work, or infringes the copyright or other rights of any third party.
post non-constructive, meaningless, one word (or short) non-sense posts.
post links to, or otherwise publish any content containing any form of advertising, promotion for goods and services, spam, or other unsolicited communication.
post any affiliate or referral links, or post anything asking for a referral.
post or otherwise publish any content unrelated to the board or the board's topic.
re-post premium share chat posts on regular share chat.
restrict or inhibit any other user from using the boards.
impersonate any person or entity, including any of our employees or representatives.
post or transmit any content that contains software viruses, files or code designed to interrupt, destroy or limit the functionality of this website or any computer software or equipment.
If you are going to post non-English, please also post an English translation of your post.
If you are going to post non-English, please also post an English translation of your post.
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium and Verified Members
Premium Members are members that have a premium subscription with London South East and have access to Premium Chat. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
SLF72: '4. Accustom is listed and has a plan to commercialisation.' Now that is totally OTT as a near term expectation! But we can dream. Where's will we find support this week, or will we break through the declining resistance?
What news do you think COULD COME OUT OF THE BLUE here in the next 6 months? I'd be sick if I missed it, but each to their own. Also, pre covid at 40p - Add the cash in the bank to that & you're probably near - 70p fair value for comparison. Is it worth being on the side lines or elsewhere? I've watched a few shares go off into the sunset, having done the hard graft. I have faith in my choice of investment and will remain invested unless news tells me a different story.
Nightmarewalking - What news do you think could come out of the blue here in the next 6 months? I cannot give a timeline, but this guy didn't join to stagnate and grow old. Any news that comes out could be company making. I look forward to you congratulating the LTH's at some point.
'New York/London, 13 January 2021 - Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases, announces the appointment of Dr Neil Graham MBBS, MD, MPH as Chief Medical Officer.
Dr Graham is a medicines development expert and Infectious Diseases Epidemiologist with global Biotech and Pharma R&D experience in Phase I-IV therapeutics as well as in-vivo & in-vitro diagnostics, across many modalities. He has in depth Global Development Expertise (e.g. Virology, Respiratory, Dermatology, Allergy, & Rheumatology) in early & late stage Clinical Development and in Medical Affairs, with a strong track record for Developing and Accelerating Phase I-IV programs. Multiple IND's, NDA/BLA filings and/or defense and multiple successful launches. From 2010 to 2020, Dr Graham was VP of Strategic Program Direction, Immunology and Inflammation at Regeneron Pharmaceuticals, Inc., where he managed and oversaw a large portion of the Regeneron pipeline portfolio including leading the immunology and inflammation antibody products across all stages of development from preclinical to post-launch.'
I would normally agree with you but the Bods appear to have changed their view to listing on NAS only, however, they could again change their view and list on both exchanges, possibly for legal reasons otherwise why did they not come out and say it in one syllable?
I still can't get over the fact that it should have be quite specific within an RNS!
All smoke and mirrors with Accustem, but why? Beggars belief.
You don't need to explain yourself to me. The point I was making was in response to your comment about selling and coming back. That would have worked a few months ago but that doesn't make sense now, this is very likely the bottom or close to the bottom.
Just like now is a good time to load up on 4D this imo is a good time to load up here and tuck them away until news comes out of the blue.
Of course it might go a bit lower no one knows, but having raised $57.25 million at an equivalent of £1.87 nine months ago I see a lot of value down here at £0.80. What price are you waiting for? 75p? 70p? 60p?
That's such rubbish I'm afraid. The people who lose the most are the ones that lose faith ONCE the share price has fallen, assume it's going to keep falling and then miss the rise. I would agree with your comments Nightmare if the share price had yet to plummet, but it has already.
The time to sell was three months, even one month ago. THIS is the time to get back in and wait.
Hmmm that was dated SEPT 2020 - "The newly listed Accustem will seek to be admitted to the standard segment of the London Stock Exchange during the fourth quarter of 2020 with a dual listing on NASDAQ on the cards for 2021.
Do I read that as a misclick - for 2020 read 2021 and for 2021 read 2022 ???!!!! or should I be thinking for 2020 read 2022 and for 2021 read 2023 ????
The Chair's primary role is to ensure that the board is effective in its task of setting and implementing the company's direction and strategy. The Chair is appointed by the board and the position may be full-time or part-time. Cut & paste - Obviously.
I'm afraid this Company treats Investors with contempt and they should wither take it private or start behaving properly. They also need to stop trying to ramp it on RedChip and start a proper grown-up Investor Relations strategy.
As for Accustem they have blatantly mis-lead Investors, either willingly or due to their own incompetence or poor corporate advice.
All this Company does is over-promise and under-deliver. Institutions who took part in the placement at a price much higher than today's cannot be happy. This post is tagged as "no opinion" because I am so tired of this company I've lost the will to have an opinion as to buy, sell, hold etc.
The science amazing, the companies transparency with regards to what is happening, disgusting. Hopefully will all come good in the end but accustem has been diabolical to say the least, and this is what causes investors to have lack of faith in what is an amazing company, hence why the share price continues to diminish. Time for this company to deal with what needs to be dealt with and not jumping from one thing to the other and making yourselves look complete fools
In the latest relevant RNS, headed "Tiziana Announces Plans to List Accustem in US", it says
"....intends to file a listing application with the Nasdaq Stock Market shortly after completion of the distribution of shares in Accustem to Tiziana Life Sciences plc shareholders.
"The board of directors of Accustem has resolved that the Nasdaq listing venue is more appropriate to the nature of Accustem's business."
That really doesn't square with your comment that "It is not written in an rns that the bods have changed from listing on both exchanges to just nas", even though it isn't quite in words of one syllable.
It is not written in an rns that the bods have changed from listing on both exchanges to just nas, which is the reason Cloudy currently has the view and I believe it should have been as the last rns on the topic has led us to assume just listing on nas. Really bad comms either way.